DRKS00026087Completed未知
Optical genome mapping in addition to cytogenetic characterization based on apparently balanced chromosome translocations
niversitätsklinikum FreiburgInstitut für Humangenetik0 sites4 target enrollmentStarted: August 13, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 4
Study Overview
Brief Summary
We emphasize the importance of a combination of conventional cytogenetics and molecular cytogenomic methods (e.g., OGM) to reveal the cause of monogenic diseases typically caused by single nucleotide variants. The combination of those different techniques in cases of reciprocally balanced translocations involving the FBN1 gene is helpful to understand the extent of the molecular etiology of Marfan syndrome. Thus, it has the potential to identify novel, clinically relevant FBN1 gene abnormalities that expand the diagnostic possibilities in patients with Marfan syndrome.
Study Design
- Study Type
- Interventional
- Allocation
- N/a: Single Arm Study
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- one to one (—)
- Sex
- All
Inclusion Criteria
- •apparently balanced chromosome translocations
Exclusion Criteria
- •inconspicuous set of chromosomes
Investigators
Similar Trials
Unknown
Not Applicable
Optical Genome Mapping for the Diagnosis of Neurodevelopmental DisordersNeurodevelopmental Disorder (Diagnosis)NCT06347562IRCCS Eugenio Medea58
Completed
Not Applicable
Optical Genome Mapping in Characterization of Multiple MyelomaMultiple MyelomaNCT05786105Institut de cancérologie Strasbourg Europe8
Recruiting
Not Applicable
Optical Genome Mapping in Hematological MalignanciesMDSALLOther Hematologic Malignant NeoplasmsNCT05009537University Hospital, Brest200
Completed
Not Applicable
Impact of Optical Genome Mapping in Acute Myeloblastic LeukemiaAcute Myeloblastic LeukemiaNCT05499611University Hospital, Bordeaux120
Completed
Not Applicable
S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood DiseaseMultiple Myeloma and Plasma Cell NeoplasmPrecancerous/Nonmalignant ConditionLymphomaNCT00898066SWOG Cancer Research Network37
